Merck And J&J Settle Remicade Dispute By Redrawing The Map
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs
You may also be interested in...
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Johnson & Johnson’s pharma business appears to be weathering headwinds that are hobbling its consumer and medical device sales. Pharma accounted for 36% of JNJ’s 2010 sales of $61.6 billion.